Many studies have focused on patients treated with allogeneic peripheral stem cell transplantation; few studies have until now been carried out to describe the characteristics and results of autografted patients and to attempt to determine possible prognostic factors. However, it is estimated that nearly 5% of autograft patients require MIR care. The investigators therefore wish to conduct a retrospective study including patients treated by therapeutic intensification followed by autograft of hematopoietic stem cells and admitted to the MIR department of the Hautepierre hospital of the University Hospitals of Strasbourg (HUS) within thirty days following initiation of chemotherapy.
Study Type
OBSERVATIONAL
Enrollment
24
Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France
Strasbourg, France
Retrospective description of the clinical and biological characteristics of patients having therapeutic intensification and autograft of peripheral stem cells for the treatment of hematological malignancy
Time frame: Thirty days following therapeutic intensification and autograft of peripheral stem cells in treatment of a malignant hematological disease.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.